12:22 PM EDT, 08/09/2024 (MT Newswires) -- Revance Therapeutics ( RVNC ) shares were more than 16% in recent trading on Friday, after it reported a decline in Q2 loss.

The company reported a Q2 net loss of $0.36 per diluted share, narrowing from a $0.80 per-share loss a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $0.48.

Revenue for the quarter ended June 30 rose to $65.4 million from $54.4 million a year earlier.

Analysts surveyed by Capital IQ expect $66.3 million.

Price: 3.44, Change: +0.49, Percent Change: +16.44